Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 38 of 48 for:    ( Map: Gabon )

Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02083380
Recruitment Status : Completed
First Posted : March 11, 2014
Results First Posted : January 30, 2017
Last Update Posted : March 10, 2017
Sponsor:
Information provided by (Responsible Party):
Medicines for Malaria Venture

Brief Summary:

A randomised, double-blind single-dose study to determine the efficacy, safety, tolerability and pharmacokinetics of OZ439 (artefenomel) in combination with piperaquine (PQP) in patients > 0.5 years and <= 70 years of age with uncomplicated Plasmodium falciparum malaria in Africa and Asia (Vietnam).

Interim analyses for futility were planned. Adults and children will be included through progressive step-down in age following safety review by an independent safety monitoring board (ISMB).

If the study were to meets its efficacy objectives, this will inform dose setting for Phase III studies.


Condition or disease Intervention/treatment Phase
Uncomplicated Plasmodium Falciparum Malaria Drug: Artefenomel 800mg: piperaquine 640mg Drug: Artefenomel 800mg: piperaquine 960mg Drug: Artefenomel 800mg: piperaquine 1440mg Phase 2 Phase 3

Detailed Description:

A randomised, double-blind single-dose (loose combination) study in the target patient population of children > 0.5 years and <= 5 years of age in Africa and patients of all ages in Asia (> 0.5 years and <= 70 years) with uncomplicated Plasmodium falciparum malaria. Patients > 5 years in Africa were also to be recruited in a safety age step down procedure. The underlying assumption was that children of 5 years or less in Africa and all ages in Asia will have a higher probability of having lower immunity and hence potentially require higher drug exposure to achieve efficacy and hence the study aimed to recruit 60-80% African children < = 5 years and 18-36% Asian patients (defined as the target population) and approximately 10% African patients >5 years,

Three OZ439/PQP treatment arms were to be included for patients >= 35 kg (800mg OZ439 in loose combination with PQP doses of either 640, 960, 1440 mg). Doses were scaled for patients < 35kg based on the weight to achieve similar exposures in patients >= 35kg.

The study was to test for futility and dose arms were to be dropped if the probability was >30% that PCR-adjusted ACPR at Day 28 (ACPR28) was less than 90% (the target efficacy for the study was >= 95% ACPR28). Only data from patients in Asia patients and Africa patients < 5 years were to be included in the Interim analysis, although all patients were to be included in the final analysis. Interim analyses were to occur after recruitment of approximately 50 evaluable patients per dose cohort and thereafter approximately after every 25 patients.

In a separate process, the safety of OZ439/PQP treatment arms was to be assessed at scheduled time points by an ISMB and adults and children were included through progressive step-down in age range following safety evaluation

Following Screening and informed consent, patients were to receive study drug and were to be followed for clinical signs of malaria (parasitaemia and temperature), safety assessments and pharmacokinetics up to Day 42 following dosing (Day 63 at selected sites).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 448 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomised Phase IIb Study of Efficacy, Safety, Tolerability & Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria.
Study Start Date : July 2014
Actual Primary Completion Date : October 2015
Actual Study Completion Date : November 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria

Arm Intervention/treatment
Experimental: A) Artefenomel 800mg: piperaquine 640mg
One single dose of Artefenomel 800mg: Piperaquine phosphate 640mg loose combination
Drug: Artefenomel 800mg: piperaquine 640mg
Active, loose combination
Other Name: OZ439 ; PQP

Experimental: B) Artefenomel 800mg: piperaquine 960mg
One single dose of Artefenomel 800mg: Piperaquine phosphate 960mg loose combination
Drug: Artefenomel 800mg: piperaquine 960mg
Active, loose combination
Other Name: OZ439 ; PQP

Experimental: C) Artefenomel 800mg: piperaquine 1440mg
One single dose of Artefenomel 800mg: Piperaquine phosphate 1440mg loose combination
Drug: Artefenomel 800mg: piperaquine 1440mg
Active, loose combination
Other Name: OZ439 ; PQP




Primary Outcome Measures :
  1. PCR-adjusted ACPR at Day 28 in the PP Population (All Patients) [ Time Frame: Day 28 ]

    Polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification. Per protocol population (PP).

    95% Clopper-Pearson 2-sided Confidence Interval (CI) constructed around the single binomial proportion per treatment arm and total.


  2. PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages) [ Time Frame: Day 28 ]

    PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.

    95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.


  3. PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages) [ Time Frame: Day 28 ]

    PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.

    95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.


  4. PCR-adjusted ACPR at Day 28 in the PP Population: Africa (> Than 5 Years) [ Time Frame: Day 28 ]

    PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.

    95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.


  5. PCR-adjusted ACPR at Day 28 in the PP Population: Africa (< = 5 Years) [ Time Frame: Day 28 ]

    PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.

    95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.


  6. PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>2 to <= 5 Years) [ Time Frame: Day 28 ]

    PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.

    95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.


  7. PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>= 0.5 to <= 2 Years) [ Time Frame: Day 28 ]

    PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.

    95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.



Secondary Outcome Measures :
  1. PCR - Adjusted ACPR at Day 42 in the PP Population [ Time Frame: Days 42 ]
    PCR - adjusted adequate clinical and parasitological response at Day 42

  2. PCR-adjusted ACPR at Day 63 in the PP Population [ Time Frame: Day 63 ]
    PCR-adjusted adequate clinical and parasitological response at Day 63

  3. Crude ACPR at Day 28 in the PP Population [ Time Frame: Day 28 ]
    Crude adequate clinical and parasitological response at Day 28

  4. Crude ACPR at Day 42 in the PP Population [ Time Frame: Day 42 ]
    Crude adequate clinical and parasitological response at Day 42

  5. Crude ACPR at Day 63 in the PP Population [ Time Frame: Day 63 ]
    Crude adequate clinical and parasitological response at Day 63

  6. PCR-adjusted ACPR at Day 28 in the ITT Population [ Time Frame: Day 28 ]
    PCR-adjusted adequate clinical and parasitological response at Day 28. Intent to Treat ( ITT) population.

  7. PCR-adjusted ACPR at Day 42 in the ITT Population [ Time Frame: Day 42 ]
    PCR-adjusted adequate clinical and parasitological response at Day 42 in the ITT population

  8. PCR-adjusted ACPR at Day 63 in the ITT Population [ Time Frame: Day 63 ]
    PCR-adjusted adequate clinical and parasitological response at Day 63 in the ITT population

  9. Crude ACPR at Day 28 in the ITT Population [ Time Frame: Day 28 ]
    Crude adequate clinical and parasitological response at Day 28 in the ITT population

  10. Crude ACPR at Day 42 in the ITT Population [ Time Frame: Day 42 ]
    Crude adequate clinical and parasitological response at Day 42 in the ITT population

  11. Crude ACPR at Day 63 in the ITT Population [ Time Frame: Day 63 ]
    Crude adequate clinical and parasitological response at Day 63 in the ITT population

  12. Kaplan-Meier Estimate of Recurrence [ Time Frame: Day 63 ]
    Kaplan-Meier estimate of number of recurrent infections (either recrudescence or new infection)

  13. Kaplan-Meier Estimate of Recrudescence [ Time Frame: Day 63 ]
    Kaplan-Meier estimate of number of patients with recrudescence

  14. Kaplan-Meier Estimate of New Infection Rate [ Time Frame: Day 63 ]
    Kaplan-Meier estimate of number of patients with new infections

  15. Parasite Clearance Time [ Time Frame: 0, 6, 12, 18, 24, 30, 36, 48 and 72 hours post dose ]
    Time post dose to parasite clearance

  16. Fever Clearance Time [ Time Frame: Day 42 ]
    Time to fever clearance (hours)

  17. PRR48 [ Time Frame: 0, 6, 12, 18, 24, 30, 36 and 48 hours post dose ]
    Parasite reduction ratio at 48 hours post dose


Other Outcome Measures:
  1. Piperaquine: Cday7 Asia (All Ages) [ Time Frame: Day 7 ]
    Piperaquine concentration at Day7 in Asian patients all ages

  2. Piperaquine: Cday7 Africa (> 5 Years) [ Time Frame: Day 7 ]
    Piperaquine concentration at Day7 in African patients > 5 years

  3. Piperaquine: Cday7 Africa (>2 to <= 5 Years) [ Time Frame: Day 7 ]
    Piperaquine concentration at Day7 in African patients > 2 and <= 5years

  4. Piperaquine: Cday7 Africa (>=0.5 to <= 2 Years) [ Time Frame: Day 7 ]
    Piperaquine concentration at Day7 in African patients >= 0.5 and <= 2 years

  5. Artefenomel Cday7 Asian Patients (All Ages) [ Time Frame: Day 7 ]
    Artefenomel concentration on Day 7 in Asian Patients (all ages). All Treatment arms.

  6. Artefenomel Cday7 African Patients (> 5 Years) [ Time Frame: Day 7 ]
    Artefenomel concentration on Day 7 in African Patients > 5 years. All Treatment arms.

  7. Artefenomel Cday7 African Patients (>2 to <= 5 Years) [ Time Frame: Day 7 ]
    Artefenomel concentration on Day 7 in African Patients >2 to <= 5 years. All Treatment arms.

  8. Artefenomel Cday7 African Patients (>=0.5 to <= 2 Years) [ Time Frame: Day 7 ]
    Artefenomel concentration on Day 7 in African Patients >= 0.5 to <=2 years. All Treatment arms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Months to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patient age >6 months <70 years.
  2. Body weight >5 kg <90 kg.
  3. Presence of mono-infection of P. falciparum with:

    1. Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,
    2. Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual parasites /µL of blood.
  4. Written informed consent provided by the adult patient, or parent or legally acceptable representative (LAR) of the minor patient or by an impartial witness (if the patient or patient's LAR is illiterate), and by the medically qualified Investigator. Children will be asked to provide assent where appropriate. The age from which this will be sought will be defined by local legislation.

Exclusion Criteria:

  1. Presence of severe malaria (according to World Health Organization (WHO) definition - WHO 2013)
  2. Anti-malarial treatment:

    1. With piperaquine -based compound, mefloquine, naphthoquine or sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their inhibition of new infections has fallen below 50%).
    2. With amodiaquine or chloroquine within the previous 4 weeks.
    3. With quinine, halofantrine, lumefantrine-based compounds and any other anti-malarial treatment or antibiotics with anti-malarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14 days.
    4. With any herbal products or traditional medicines, within the past 7 days.
  3. Known history or evidence of clinically significant disorders such as, respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological, neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including head trauma).
  4. Family history of sudden death or of congenital or clinical conditions known to prolong QTcB or QTcF interval or e.g. patients with a history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.
  5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.
  6. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction.
  7. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.
  8. Any treatment which can induce a lengthening of QT interval, such as:

    1. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol),
    2. Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine),
    3. Anti-depressive agents, certain antimicrobial agents, including agents of the following classes macrolides (e.g. erythromycin, clarithromycin), fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole antifungal agents, and also pentamidine and saquinavir,
    4. Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine), cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.
    5. Anti-emetics with known QT prolongation potential such as domperidone
  9. Mixed Plasmodium infection
  10. Severe vomiting, defined as more than three times in the 24 hours prior to enrolment in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3 or more watery stools per day
  11. Severe malnutrition (defined for subjects aged ten years or less as the weight-for-height being below -3 standard deviation or less than 70% of median of the National Centre for Health Statistics (NCHS)/WHO normalised reference values, and for subjects aged greater than ten years, a body mass index (BMI) of less than 16 (WFP Manual, Chapter 1)).
  12. Known history of hypersensitivity, allergic or adverse reactions to piperaquine or other aminoquinolones or to OZ439 or OZ277
  13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).
  14. If Total Bilirubin is normal, exclude the patient if liver function tests Aspartate transaminase (AST)/ Alanine transaminase (ALT) ≥ 2x Upper limit of normal (ULN).
  15. If Total Bilirubin is > 1 and ≤ 1.5xULN, exclude the patient if AST/ALT >1.5xULN.
  16. Total Bilirubin > 1.5XULN
  17. Haemoglobin level below 8 g/dL.
  18. Serum creatinine levels ≥2 x ULN
  19. Female patients of child bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures not to become pregnant during the study period and safety follow-up period.
  20. Have received an investigational drug within the past 4 weeks.
  21. Previous participation in any malaria vaccine study or received malaria vaccine in any other circumstance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02083380


Locations
Layout table for location information
Benin
Centre D'Étude Et de Recherchesur Le Paludisme Associé À La Grossesse Et À L'Enfance (Cerpage) Cerpage
Cotonou, Benin, FSS 01 BP 188
Burkina Faso
Centre National de Recherche et de Formation sur le paludisme (CNRFP) Ouagadougou, Kadiogo
Ouagadougou, Burkina Faso
Clinical research Unit of Nanoro (CRUN)/CMA Saint Camille de Nanoro, 11 BP 218 Ouagadougou CMS 11
Ouagadougou, Burkina Faso
Congo, The Democratic Republic of the
Kinshasa School of Public Health, School of Medicine University of Kinshasa
Kinshasa, Congo, The Democratic Republic of the
Gabon
Centre de Recherches Medicales de Lambarene, Albert Schweitzer Hospital
Lambarene, Gabon
arielle K. Bouyou-Akotet, Department of Parasitology-Mycology and Tropical Medicine, Faculty of Medicine, Université des Sciences de la Santé, BP 4009, Libreville, Gabon
Libreville, Gabon
Mozambique
MANHIÇA HEALTH RESEARCH CENTER, Rua 12, Vila da Manhica, Maputa,
Chefe Maputa, Mozambique
Uganda
Tororo District Hospital
Tororo, Uganda
Vietnam
National Institute of Malariology, Parasitology and Entomology, 245 Luong The Vinh Street, Trung van, Tu Liem, Hanoi, Vietnam
Hanoi, Vietnam
Sponsors and Collaborators
Medicines for Malaria Venture
Investigators
Layout table for investigator information
Study Director: Fiona Macintyre, PhD Medicines for Malaria Venture (MMV)
Principal Investigator: Michael Ramharter, MD CERMEL (Centre de Recherches Médicale de Lambaréné)

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Medicines for Malaria Venture
ClinicalTrials.gov Identifier: NCT02083380     History of Changes
Other Study ID Numbers: MMV_OZ439_13_003
First Posted: March 11, 2014    Key Record Dates
Results First Posted: January 30, 2017
Last Update Posted: March 10, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Medicines for Malaria Venture:
Plasmodium falciparum malaria
malaria
OZ439
piperaquine
PQP
Additional relevant MeSH terms:
Layout table for MeSH terms
Malaria
Malaria, Falciparum
Protozoan Infections
Parasitic Diseases
Piperaquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents